UK markets close in 5 hours 49 minutes
  • FTSE 100

    7,584.13
    -5.53 (-0.07%)
     
  • FTSE 250

    22,710.68
    +55.66 (+0.25%)
     
  • AIM

    1,151.05
    +1.56 (+0.14%)
     
  • GBP/EUR

    1.2007
    +0.0008 (+0.06%)
     
  • GBP/USD

    1.3621
    +0.0009 (+0.07%)
     
  • BTC-GBP

    30,884.91
    +250.09 (+0.82%)
     
  • CMC Crypto 200

    999.30
    +4.55 (+0.46%)
     
  • S&P 500

    4,532.76
    -44.35 (-0.97%)
     
  • DOW

    35,028.65
    -339.82 (-0.96%)
     
  • CRUDE OIL

    86.75
    -0.21 (-0.24%)
     
  • GOLD FUTURES

    1,837.10
    -6.10 (-0.33%)
     
  • NIKKEI 225

    27,772.93
    +305.70 (+1.11%)
     
  • HANG SENG

    24,952.35
    +824.50 (+3.42%)
     
  • DAX

    15,793.23
    -16.49 (-0.10%)
     
  • CAC 40

    7,137.63
    -35.35 (-0.49%)
     

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with unresectable locally advanced and metastatic non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Further information:

Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting